Pichia pastoris genetically engineered bacterium for high yield of lycopene

By integrating and regulating specific gene combinations and signal peptide targeting sequences in Pichia cerevisiae strain TX-L3, the metabolic pathway was optimized, and the problem of low lycopene synthesis was solved, and efficient lycopene synthesis was achieved, especially in The yields in zw327 and zw352 strains were significantly improved.

CN119081903APending Publication Date: 2024-12-06EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411254204.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, lycopene has a low synthesis yield in yeasts, and it is difficult to balance cell growth and product synthesis by regulating the activity of ERG9p, resulting in limited yield improvement.

Method used

By integrating specific gene combinations and signal peptide targeting sequences in Pichia schizophrenia strain TX-L3, the expression of CrtI, CrtYB and CrtE genes is regulated, combined with the promoter of ERG9 and the integration of other metabolic pathway genes, the metabolic pathways are optimized to improve the Lycopene yield.

Benefits of technology

The yield of lycopene was significantly improved, especially the yield of engineered strains zw327 and zw352 in the 5L fermenter reached 8.4g/L and 10.2g/L, respectively, and efficient lycopene synthesis was achieved under different conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119081903A_ABST
    Figure CN119081903A_ABST
Patent Text Reader

Abstract

The invention discloses a pichia pastoris genetically engineered bacterium for high yield of lycopene, which is prepared by using exogenous genes CrtE, CrtYBW61R and CrtI for coding GGPPs (Glycine Growth Peptide Protein), lycopene synthetase and lycopene dehydrogenase in the previous research of the inventor, and a pichia pastoris strain TX-L3 capable of synthesizing lycopene is obtained by positioning a tHMG1 gene for coding HMG-CoA reductase in cytoplasm and is used as an original strain, and the high-yield lycopene engineering strain is obtained by carrying out step-by-step modification on the original strain. In the obtained pichia pastoris engineering bacteria with high lycopene yield, the results of the strains zw327 and zw352 are most prominent, and the lycopene yield of the strain zw327 fermented by a 5-liter bioreactor is up to 8.4 g / L; in the fermentation process of the strain zw352, a mode of combining glycerol supplement with methanol induction is adopted, and the yield of lycopene reaches 10.2 g / L.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a genetically engineered Pichia yeast with high lycopene production. Background Art

[0002] Lycopene, as an important member of the carotenoid family, is a fat-soluble polyunsaturated olefin compound with strong antioxidant capacity due to its excellent singlet oxygen quenching ability or ability to capture superoxide free radicals. Therefore, it is widely used in cosmetics, medicines, food additives and other fields.

[0003] Traditional lycopene production methods are mainly through natural extraction from fruits and vegetables, but due to the low extraction yield, it is difficult to meet the growing market demand. Chemical synthesis is also feasible, but due to its complex structure, the process is complicated and costly, and it also brings environmental pollution and health problems. In contrast, microbial fermentation provides a more economical and sustainable alternative method, making large-scale lycopene synthesis possible.

[0004] As early as the 1990s, lycopene has been heterologously synthesized in Escherichia coli and Saccharomyces cerevisiae. To date, the highest yield has reached 448 mg / g dry cell weight (DCW) in E. coli. However, endotoxins released by E. coli pose significant food safety issues. Therefore, using GRAS yeast as a host for heterologous synthesis of lycopene may be a better choice. Zhou Kui et al. successfully increased the lycopene production in Saccharomyces cerevisiae through adaptive evolution, reaching 8.15 g / L in a 7L fermenter. In addition, Ma Yongshuo et al. increased the lycopene production in Yarrowia oleifera by redistributing carbon flux and using protein engineering.

[0005] As a methylotrophic yeast, Pichia pastoris is able to use methanol as the sole carbon source and energy source for high-density fermentation and synthesis of high-value-added chemicals in simple culture media, which has attracted great interest from researchers. In particular, methanol, a non-food liquid C1 feedstock, can be produced by hydrogenation of CO2, which has the advantages of low cost, easy access and easy transportation, and is expected to mitigate the greenhouse effect. In addition, the degree of reduction of each carbon atom in methanol is higher than that of glucose and glycerol, so it is theoretically more conducive to the synthesis of reduced chemicals such as terpenes and alcohols. In recent years, in-depth research on CRISPR-based gene editing technology has led to the widespread application of Pichia pastoris in the synthesis of a variety of high-value chemicals from methanol, including terpenes, fatty acids, chondroitin sulfate, etc. However, there are currently few studies on lycopene biosynthesis in Pichia pastoris.

[0006] Isoprenyl pyrophosphate (FPP) is an endogenous precursor for lycopene biosynthesis. In yeast, FPP is catalyzed by squalene synthase (ERG9p) to produce squalene, which is subsequently converted to ergosterol, which is essential for growth. Therefore, it is unrealistic to knock out squalene synthase to direct FPP to lycopene synthesis. Therefore, the allocation of FPP flow is crucial to balance cell growth and lycopene biosynthesis. Rational regulation of ERG9p activity is an effective strategy to reduce non-productive consumption of FPP. Recently, Zhang Xinying et al. increased lycopene production by inhibiting downstream competing pathways through CRISPRi, but failed to dynamically balance cell growth and product synthesis. Therefore, a more flexible strategy to regulate the activity of ERG9p is urgently needed.

[0007] Excessive carotenoid accumulation has been shown to integrate into lipid-rich regions such as the plasma membrane and lipid droplets, leading to cell membrane damage and oxidative stress. Subcellular sequestration is an effective strategy for efficient synthesis of high-value chemicals in cell factories, which can not only improve the synthesis efficiency but also reduce the toxicity of the products to cells. In particular, the single-membrane peroxisome, whose interior has been verified to have a hydrophobic environment, is an ideal place for terpenoid synthesis and storage. Summary of the invention

[0008] In previous studies, the inventors of the present application inserted the exogenous genes CrtE and CrtYB encoding geranylgeranyl pyrophosphate synthase (GGPPs), lycopene synthase and lycopene dehydrogenase into the W61R The inventors modified the metabolic pathway of TX-L3 step by step and successfully obtained a series of genetically engineered bacteria with significantly improved lycopene production.

[0009] Therefore, in the first aspect of the present invention, there is provided a high-yield lycopene Pichia pastoris genetically engineered bacterium zw113, wherein the engineered bacterium zw113 is based on the Pichia pastoris strain TX-L3, and the P GAP and T DAS2 The CrtI gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused to the C-terminus. GAP -CrtI-ePTS1-T DAS2 , respectively, with P GAP and T FBA1 The CrtYB gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused at the C-terminus. GAP -CrtYB W61R -ePTS1-TFBA1 , and P GAP and T CAT1TT The CrtE gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused at the C terminus. GAP -CrtE-ePTS1-T CAT1TT And get, among which:

[0010] The GenBank accession number of gene CrtI is: AY177424.1, the GenBank accession number of gene CrtYB is: AY177204.1, the GenBank accession number of gene CrtE is: DQ016502.1, and the above genes have been codon-optimized according to the preference of Pichia pastoris.

[0011] In a second aspect of the present invention, there is provided a high-yield lycopene Pichia pastoris genetically engineered bacterium zw137, wherein the engineered bacterium zw137 is based on the above-mentioned engineered bacterium zw113 as a starting strain, and the promoter of ERG9 encoding squalene synthase is replaced by P ERG8 -Ubi-KN113, where:

[0012] P ERG8 It is the promoter of the endogenous gene ERG8 encoding phosphomevalonate kinase in Pichia pastoris, and the NCBI accession number of the gene ERG8 is XM_002491823.1; Ubi is an endogenous ubiquitin protein gene, and its GenBank accession number is CAH2450568.1; KN113 is a protein N-terminal degradation signal sequence.

[0013] The third aspect of the present invention provides a high-yield lycopene Pichia pastoris genetically engineered strain zw205, wherein the engineered strain zw205 is based on the above-mentioned engineered strain zw137, and the II-6 sites are integrated with P GAP and T AOX1 MVD1 gene P GAP -MVD1-T AOX1 The NCBI accession number of MVD1 is: XM_002490072.1.

[0014] In a fourth aspect of the present invention, there is provided a high-yield lycopene Pichia pastoris genetically engineered bacterium zw243, wherein the engineered bacterium zw243 is based on the above-mentioned engineered bacterium zw205 as the starting strain, and the II-4 sites of the engineered bacterium are respectively integrated with P GAP and T PMP20 ERG10 gene P GAP -ERG10-T PMP20The NCBI accession number of ERG10 is: XM_002490381.1.

[0015] The fifth aspect of the present invention provides a high-yield lycopene Pichia pastoris genetically engineered bacterium zw267, wherein the engineered bacterium zw267 is based on the above-mentioned engineered bacterium zw243 as the starting strain, and the III-4 sites of the engineered bacterium are respectively integrated with P GAP and T PMP20 The CrtE and ERG20 genes are linked by GGGGS. GAP -CrtE-GGGGS-ERG20-T PMP20 It was obtained that the NCBI accession number of gene ERG20 is: XM_002490391.1.

[0016] In a sixth aspect of the present invention, there is provided a high-yield lycopene Pichia pastoris genetically engineered bacterium zw327, wherein the engineered bacterium zw327 is based on the above-mentioned engineered bacterium zw267 as a starting strain, and the P GAP and T PMP20 PAS_Chr2-2_0003 gene P GAP -PAS_Chr2-2_0003-T PMP20 The NCBI accession number of gene PAS_Chr2-2_0003 is: XM_002492168.1.

[0017] The seventh aspect of the present invention provides a high-yield lycopene Pichia pastoris genetically engineered bacterium zw303, wherein the engineered bacterium zw303 is based on the above-mentioned engineered bacterium zw267 as the starting strain, and the II-5 site is integrated with P AOX1 and T Gcw14 The DAS1 gene P AOX1 -DAS1-T Gcw14 , respectively, P AOX1 and T TPI1 The promoter and terminator of the RKI1 gene P AOX1 -RKI1-T TPI1 , and P AOX1 and T GCW14 TAL2 gene P AOX1 -TAL2-T GCW14 And get, among which:

[0018] The NCBI accession number of gene DAS1 is: XM_002493018.1, the NCBI accession number of RKI1 is: XM_002493573.1, and the NCBI accession number of TAL2 is: XM_002491803.1.

[0019] In an eighth aspect of the present invention, there is provided a high-yield lycopene Pichia pastoris genetically engineered bacterium zw306, wherein the engineered bacterium zw306 is based on the above-mentioned engineered bacterium zw303 as a starting strain, and the DNA ligase IV sites of the engineered bacterium are respectively integrated with P AOX1 and T DAS2 The AnXfpk gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused at the C-terminus. AOX1 -AnXfpk-ePTS1-T DAS2 , and P GAP and T TPI1 The BsuPta gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused to the C-terminus. GAP -BsuPta-ePTS1-T TPI1 And get, among which:

[0020] The GenBank accession number of gene AnXfpk is: XP_001399780.1, and the GenBank accession number of BsuPta is: WP_003243393.1.

[0021] The ninth aspect of the present invention provides a high-yield lycopene Pichia pastoris genetically engineered strain zw352, wherein the engineered strain zw352 is based on the above-mentioned engineered strain zw303, and the P AOX1 and T PMP20 PAS_Chr2-2_0003 gene P GAP -PAS_Chr2-2_0003-T PMP20 The NCBI accession number of gene PAS_Chr2-2_0003 is: XM_002492168.1.

[0022] The present invention has the following beneficial effects:

[0023] 1. The present invention uses Pichia pastoris strain TX-L3 as the starting strain, attempts a number of metabolic pathway transformation strategies, and screens and obtains a number of genetically engineered strains, from which the yield of lycopene is significantly improved.

[0024] 2. Among the engineered bacteria with high lycopene production, strains zw327 and zw352 showed the most outstanding results. The lycopene production of strain zw327 reached 8.4 g / L after fermentation in a 5-liter bioreactor. During the fermentation process of strain zw352, glycerol feeding combined with methanol induction was used, and the lycopene production reached 10.2 g / L. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Schematic diagram of the synthesis of lycopene.

[0026] In the figure: Glucose is glucose, Acetyl-CoA is acetyl-CoA, Acetoacetyl-CoA is acetoacetyl-CoA, HMG-CoA is glutaryl-CoA, MVA is mevalonate, MVA-5-P is 5-phosphomevalonate, MVA-5-PP is 5-pyrophosphatemevalonate, IPP is isoprene pyrophosphate, DMAPP is dimethylallyl pyrophosphate, GPP is geranyl pyrophosphate synthase, FPP is isoprene pyrophosphate, Squalene is squalene synthase, Ergosterol is ergosterol, GGPP is geranylgeranyl pyrophosphate synthase, Phytoene is lycopene, Lycopene is lycopene, Peroxisome is peroxisome, Cell membrane is cell membrane, and Cytoplasm is cytoplasm. DETAILED DESCRIPTION

[0027] The present invention is further described in detail by specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0028] The sources of the experimental materials used in the following examples are as follows:

[0029] Pichia pastoris X33: a commercial strain, which can be obtained through conventional commercial channels.

[0030] Pichia pastoris TX-L3: constructed according to the method disclosed in the literature "CRISPR / Cas9-based toolkit for rapid marker recycling and combinatorial libraries in Komagataella phaffii".

[0031] Promoter P GAP , P AOX1 and terminator T DAS2 , T FBA1 , T CAT1TT , T AOX1 , T PMP20 , TGcw14 , T TPI1 , T ADH2 , T GCW14 It has been disclosed in the document "A Toolbox of Diverse Promoters Related to Methanol Utilization: Functionally Verified Parts for Heterologous Pathway Expression in Pichiapastoris".

[0032] The integration site DNA ligase IV has been disclosed in the document “CRISPR / Cas9-based toolkit for rapid marker recycling and combinatorial libraries in Komagataella phaffii”; the integration sites III-4, III-10, II-4, II-5, II-6, and I-2 have been disclosed in the document “Recombination machinery engineering facilitates metabolic engineering of the industrial yeast Pichiapastoris”.

[0033] The signal peptide ePTS1 has been disclosed in the document “Towards repurposing the yeast peroxisome for compartmentalizing heterologous metabolic pathways”.

[0034] The protein N-terminal degradation signal sequence KN113 has been disclosed in the literature “Degradation signals in the lysine-asparagine sequence space”.

[0035] The YPD medium, MY medium, MM medium and BSM medium used in the following examples are all conventional culture media in the art and can be obtained through conventional commercial channels.

[0036] The sequences of the primers used in the following examples are shown in Tables 1 and 2.

[0037] Table 1: Primer sequences for plasmid construction

[0038]

[0039]

[0040]

[0041] Table 2: Primer sequences for engineering bacteria construction

[0042]

[0043]

[0044]

[0045] The genetic engineering operation methods involved in the following examples, unless otherwise specified, are all conventional operations in the art, or are performed in accordance with the instructions of relevant products.

[0046] Example 1. Construction of expression cassette plasmid

[0047] 1.1. Construction of plasmid pGS384

[0048] S1: First, design primers for amplifying the plasmid backbone: XGHOF / Knout-R, use plasmid pGS287 (GenBank: OR763066.1) as a template, obtain the plasmid backbone fragment by PCR, and recover the target fragment by gel electrophoresis; design primers pGAP-F-XGHOF / pGAP-R, DAS2TT-F-ePTS1 / DAS2TT-R-Knout, use the X33 strain genome as a template, and PCR amplify the corresponding promoter P GAP and terminator T DAS2 DNA fragment; designed primers CrtI-F-pGAP / CrtI-R-ePTS1, and used plasmid pCrtI (GenBank: OR763075.1) as template to obtain the CrtI-ePTS1 gene fragment by PCR.

[0049] S2: Use primers pGAP-F-XGHOF / DAS2TT-R-Knout to promoter P GAP , terminator T DAS2 and gene CrtI as templates, and fusion PCR was performed to obtain fragment P GAP -CrtI-ePTS1-T DAS2 .

[0050] S3: The plasmid backbone fragment obtained in S1 and the fragment P obtained in S2 are GAP -CrtI-ePTS1-T DAS2The circular connection system was connected by seamless cloning, and transformed into Escherichia coli DH5α competent cells. After Amp resistance plate screening and colony PCR and sequencing verification, the successfully constructed positive recombinant plasmid pGS384 was obtained.

[0051] 1.2. Construction of other plasmids

[0052] The construction of plasmids pGS440, pGS615, pGS624, pGS309, pGS689, pLT50, pGS459, pGS455, pGS520, pGS490, pGS489, and pGS669 refers to the process of 1.1, the difference is that the primers used are different, as follows:

[0053] pGS440 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. GAP The primers used were pGAP-F-XGHOF / pGAP-R, which amplified the terminator T CAT1 The primers for amplifying the CrtE-ePTS1 gene fragment were CAT1TT-F-ePTS1 / CAT1TT-R-Knout, and the template was the X33 strain genome. The primers for amplifying the CrtE-ePTS1 gene fragment were CrtE-F-pGAP / CrtE-R-ePTS1, and the template was plasmid pCrtE (GenBank: OR763076.1). GAP -CrtE-ePTS1-T CAT1 The primer was pGAP-F-XGHOF / CAT1TT-R-Knout, and the template was the promoter fragment P GAP , terminator fragment T CAT1 and gene fragment CrtE-ePTS1. The seamless cloning fragments are the plasmid backbone and fragment P GAP -CrtE-ePTS1-T CAT1 .

[0054] pGS615 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. GAP The primers used were pGAP-F-XGHOF / pGAP-R-CrtYB, and the terminator T FBA1 The primers used were FBA1TT-F-ePTS1 / FBA1TT-R-Knout and the template was the genome of strain X33. W61R -The primer for the ePTS1 gene fragment is CrtYB W61R -F-pGAP / CrtYB W61R-R-ePTS1, the template is plasmid pCrtYB (GenBank: OR763074.1). Used for fusion PCR amplification fragment P GAP -CrtYB W61R -ePTS1-T FBA1 The primer was pGAP-F-XGHOF / FBA1TT-R-Knout, and the template was the promoter fragment P GAP , terminator fragment T FBA1 and gene fragment CrtYB W61R -ePTS1. Seamless cloning fragments are plasmid backbone and fragment P GAP -CrtYB W61R -ePTS1-T FBA1 .

[0055] pGS624 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. GAP The primers used were pGAP-F-XGHOF / pGAP-R, which amplified the terminator T ADH2 The primers used for PCR amplification are ADH2TT-F-ERG9 / ADH2TT-R-Knout, and the template is the X33 strain genome. The primers used to amplify the KN113-ERG9 gene fragment are ERG9-F-KN113 / ERG9-R-ADH2TT, and the template is the X33 strain genome. The primers used to amplify the Ubi gene fragment are PpUbi-F-pGAP / PpUbi-R-KN113, and the template is the X33 strain genome. Then, the primers PpUbi-F-pGAP / KN113 are used to amplify the fragment Ubi-KN113, and the template is the fragment Ubi. The primers used for fusion PCR amplification of the Ubi-KN113-ERG9 fragment are PpUbi-F-pGAP / ERG9-R-ADH2TT, and the templates are the fragments Ubi-KN113 and KN113-ERG9. The primers used for fusion PCR amplification of the fragment P GAP -Ubi-KN113-ERG9-T ADH2 The primer was pGAP-F-XGHOF / ADH2TT-R-Knout, and the template was the promoter fragment P GAP , terminator fragment T ADH2 and gene fragment Ubi-KN113-ERG9. The seamless cloning fragments are the plasmid backbone and fragment P GAP -Ubi-KN113-ERG9-T ADH2 .

[0056] pGS309 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. GAPThe primers used were pGAP-F-XGHOF / pGAP-R, which amplified the terminator T PMP20 The primers for amplifying the ERG10 gene fragment were PMP20TT-F-ERG10 / PMP20TT-R-Knout, the primers for amplifying the ERG10 gene fragment were ERG10-F-pGAP / ERG10-R-PMP20TT, and the template was the X33 strain genome. GAP -ERG10-T PMP20 The primers were pGAP-F-XGHOF / PMP20TT-R-Knout and the template was the promoter fragment P GAP , terminator fragment T PMP20 and gene fragment ERG10. The seamless cloning fragments are the plasmid backbone and fragment P GAP -ERG10-T PMP20 .

[0057] pGS689 construction: The primers for plasmid backbone amplification were CrtE-R-linker / Knout-R, and the template was pGS440. PMP20 The primers for fusion PCR amplification of ERG20-T were PMP20TT-F-ERG20 / PMP20TT-R-Knout, the primers for amplifying ERG20 gene were ERG20-F-linker / ERG20-R-PMP20TT, and the template was the X33 strain genome. PMP20 The primers for the gene fragment were ERG20-F-linker / PMP20TT-R-Knout, and the template was fragment ERG20 and the terminator fragment T PMP20 The seamless cloning fragments are the plasmid backbone and the fragment ERG20-T PMP20 .

[0058] pLT50 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. GAP The primers used were pGAP-F-XGHOF / pGAP-R, which amplified the terminator T AOX1 The primers for PCR amplification were AOX1TT-F-MVD1 / AOX1TT-R-Knout, the primers for amplifying the MVD1 gene fragment were MVD1-F-pGAP / MVD1-R-AOX1TT, and the template was the X33 strain genome. GAP -MVD1-T AOX1 The primer was pGAP-F-XGHOF / AOX1TT-R-Knout, and the template was the promoter fragment P GAP , terminator fragment T AOX1 and gene fragment MVD1. The seamless cloning fragments are the plasmid backbone and fragment PGAP -MVD1-T AOX1 .

[0059] pGS459 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. AOX1 The primers used were pAOX1-F-Knout / pAOX1-R-AnXfpk, and the terminator T DAS2 The primers for amplifying the AnXfpk-ePTS1 gene fragment were DAS2TT-F-ePTS1 / DAS2TT-R-XGHOF, and the template was the X33 strain genome. The primers for amplifying the AnXfpk-ePTS1 gene fragment were AnXfpk-F-pAOX1 / AnXpk-R-ePTS1, and the template was the codon-optimized AnXfpk gene fragment (SEQ ID NO.1). AOX1 -Anxfpk-ePTS1-T DAS2 The primer was pAOX1-F-Knout / DAS2TT-R-XGHOF, and the template was the promoter fragment P AOX1 , terminator fragment T DAS2 and gene fragment Anxfpk-ePTS1. The seamless cloning fragments are the plasmid backbone and fragment P AOX1 -Anxfpk-ePTS1-T DAS2 .

[0060] pGS455 construction: The primers for plasmid backbone amplification were XGHOF / KnOut-R, and the template was pGS287. GAP The primers used were pGAP-F-XGHOF / pGAP-R, which amplified the terminator T TPI1 The primers for amplifying the BsuPta-ePTS1 gene fragment were TPI1TT-F-ePTS1 / TPI1TT-R-Knout, and the template was the X33 strain genome. The primers for amplifying the BsuPta-ePTS1 gene fragment were BsuPta-F-pGAP / BsuPta-R-ePTS1, and the template was the codon-optimized BsuPta gene fragment (SEQ ID NO.2). GAP -BsuPta-ePTS1-T TPI1 The primer was pGAP-F-XGHOF / TPI1TT-R-Knout, and the template was the promoter fragment P GAP , terminator fragment T TPI1 and gene fragment BsuPta-ePTS1. The seamless cloning fragments are the plasmid backbone and fragment P GAP -BsuPta-ePTS1-T TPI1 .

[0061] pGS520 construction: The primers for plasmid backbone amplification were XGHOF / KnOut-R, and the template was pGS287. AOX1 The primers used were pAOX1-F-XGHOF / pAOX1-R, which amplified the terminator T Gcw14 The primers for amplifying the DAS1 gene fragment were Gcw14TT-F-DAS1 / Gcw14TT-R-Knout, the primers for amplifying the DAS1 gene fragment were DAS1-F-pAOX1 / DAS1-R-Gcw14TT, and the template was the X33 strain genome. AOX1 -DAS1-T Gcw14 The primer was pAOX1-F-XGHOF / Gcw14TT-R-Knout, and the template was the promoter fragment P AOX1 , terminator fragment T Gcw14 and gene fragment DAS1. The seamless cloning fragments are the plasmid backbone and fragment P AOX1 -DAS1-T Gcw14 .

[0062] pGS490 construction: The primers for plasmid backbone amplification were XGHOF / KnOut-R, and the template was pGS287. AOX1 The primers used were pAOX1-F-XGHOF / pAOX1-R, which amplified the terminator T TPI1 The primers for amplifying the RKI1 gene fragment are TPI1TT-F-RKI1 / TPI1TT-R-Knout, the primers for amplifying the RKI1 gene fragment are RKI1-F-pAOX1 / RKI1-R-TPI1TT, and the template is the X33 strain genome. AOX1 -RKI1-T TPI1 The primer was pAOX1-F-XGHOF / TPI1TT-R-Knout, and the template was the promoter fragment P AOX1 , terminator fragment T TPI1 and gene fragment RKI1. The seamless cloning fragments are the plasmid backbone and fragment P AOX1 -RKI1-T TPI1 .

[0063] pGS489 construction: The primers for plasmid backbone amplification were XGHOF / KnOut-R and the template was pGS287. AOX1 The primers used were pAOX1-F-XGHOF / pAOX1-R, which amplified the terminator T Gcw14The primers for PCR amplification were Gcw14TT-F-TAL2 / Gcw14TT-R-Knout, the primers for amplifying the TAL2 gene fragment were TAL2-F-pAOX1 / TAL2-R-Gcw14TT, and the template was the X33 strain genome. AOX1 -TAL2-T Gcw14 The primer was pAOX1-F-XGHOF / Gcw14TT-R-Knout, and the template was the promoter fragment P AOX1 , terminator fragment T Gcw14 and gene fragment TAL2. The seamless cloning fragments are the plasmid backbone and fragment P AOX1 -TAL2-T Gcw14 .

[0064] pGS669 construction: The primers for plasmid backbone amplification were XGHOF / Knout-R and the template was pGS287. GAP The primers used were pGAP-F-XGHOF / pGAP-R, which amplified the terminator T PMP20 The primers for amplifying the PAS_chr2-2_0003 gene fragment were PMP20TT-F-0003 / PMP20TT-R-Knout, the primers for amplifying the PAS_chr2-2_0003 gene fragment were 0003-F-pGAP / 0003-R-PMP20TT, and the template was the X33 strain genome. GAP -PAS_chr2-2_0003-T PMP20 The primers were pGAP-F-XGHOF / PMP20TT-R-Knout and the template was the promoter fragment P GAP , terminator fragment T PMP20 and gene fragment PAS_chr2-2_0003. The seamless cloning fragments are the plasmid backbone and fragment P GAP -PAS_chr2-2_0003-T PMP20 .

[0065] Example 2: Construction of Pichia pastoris genetically engineered strain zw113

[0066] In previous studies, the inventors introduced the exogenous genes CrtE, CrtYB encoding geranylgeranyl pyrophosphate synthase (GGPPs), lycopene synthase and lycopene dehydrogenase into W61R and CrtI, as well as the tHMG1 gene encoding HMG-CoA reductase (GenBank: NM_001182434.1) located in the cytoplasm, a Pichia pastoris strain TX-L3 capable of synthesizing lycopene was obtained, with a yield of 182.73 mg / L. Figure 1As shown in the schematic diagram of lycopene synthesis, based on strain TX-L3, this example introduces an additional copy of CrtE, CrtI and CrtYB into strain TX-L3 that targets the peroxisome through the targeting signal peptide ePTS1. W61R gene in order to further increase lycopene production.

[0067] 2.1. Construction of engineered bacteria

[0068] TX-L3 was used as the starting strain, and P was integrated into its III-10 site. GAP as promoter and T DAS2 The CrtI gene with the peroxisome targeting signal peptide ePTS1 fused to its C-terminus (P GAP -CrtI-ePTS1-T DAS2 ), with P GAP as promoter and T FBA1 The CrtYB gene with the peroxisome targeting signal peptide ePTS1 fused to its C-terminus (P GAP -CrtYB W61R -ePTS1-T FBA1 ), and P GAP as promoter and T CAT1TT The CrtE gene with the peroxisome targeting signal peptide ePTS1 fused to its C-terminus (P GAP -CrtE-ePTS1-T CAT1TT ) to obtain the engineered bacteria zw113.

[0069] Among them, the GenBank accession number of gene CrtI is: AY177424.1, the GenBank accession number of gene CrtYB is: AY177204.1, the GenBank accession number of gene CrtE is: DQ016502.1, and the above genes are all codon-optimized according to the preference of Pichia pastoris.

[0070] The specific steps are as follows:

[0071] 1) First, design for integration of CrtE-ePTS1, CrtI-ePTS1 and CrtYB at site III-10 W61R -The upstream and downstream homology arm primers of the ePTS1 expression cassette, the upstream homology arm primer is III-10-UHA-F / III-10-UHA-R, and the downstream homology arm primer is III-10-DHA-F / III-10-DHA-R; using the genome of the X33 strain as a template, PCR was performed to obtain DNA fragments of about 1000 bp each for the upstream and downstream homology arms of the corresponding gene;

[0072] 2) Design primers pGAP-F-III-10-UHA / DSA2TT-R-pGAP, pGAP-F-DAS2TT / FBA1TT-R-pGAP, and pGAP-F-FBA1TT / CAT1TT-R-III-10-DHA, and amplify fragment P from plasmids pGS384, pGS615, and pGS440 by PCR, respectively. GAP -CrtI-ePTS1-T DAS2 , P GAP -CrtYB W61R -ePTS1-T FBA1 and P GAP -CrtE-ePTS1-T CAT1 ;

[0073] 3) Primers gRNA-III-10-F / gRNA-III-10-R were designed according to the targeting sequence of site III-10 and ligated to plasmid pGS327 (GenBank accession number: OR298114) by T4 ligase to obtain gRNA plasmid pGS581;

[0074] 4) The upstream and downstream homology arms of site III-10, P GAP -CrtI-ePTS1-T DAS2 , P GAP -CrtYB W61R -ePTS1-T FBA1 and P GAP -CrtE-ePTS1-T CAT1 The expression cassette fragment, together with the pGS581 plasmid, was concentrated using a nucleic acid concentration kit (Magen, Guangzhou) to prepare Donor DNA, which was then introduced into Pichia pastoris TX-L3 competent cells by electroporation. The electroporation was performed using bacterial mode 1 (2.5 KV, 5 ms), and positive transformants were selected using geneticin.

[0075] 5) Design verification primers DAS2TT-F and FBA1TT-F, and use primers III-10-UHA-F / DSA2TT-R-pGAP, DAS2TT-F / FBA1TT-R-pGAP, and FBA1TT-F / III-10-DHA-R to verify whether the exogenous expression cassette has been successfully integrated by colony PCR, and confirm whether it has been correctly integrated by nucleic acid sequencing.

[0076] Sequencing results showed that CrtE-ePTS1, CrtI-ePTS1 and CrtYB W61R -The ePTS1 expression cassette has been successfully integrated into the III-10 site, and there is no mutation at the interface.

[0077] Successfully integrated CrtE-ePTS1, CrtI-ePTS1 and CrtYB W61R -ePTS1 expression cassette Pichia pastoris transformants were cultured alternately in test tubes and plates for four generations at 30°C; single colonies were isolated and then tested for resistance. Colonies that grew only on non-resistant plates but not on geneticin-resistant plates were selected for identification. Yeast colonies without geneticin resistance were colonies in which gRNA plasmid pGS581 had been eliminated and were named zw113.

[0078] 2.2 YPD shake flask fermentation

[0079] Pick a single colony of the engineered bacteria zw113 obtained in 2.1 on the plate, inoculate it into a 250 mL conical flask filled with 15 mL YPD medium and culture it for 24 to 36 h, then transfer it to a 250 mL conical flask filled with 50 mL YPD medium to control the initial OD 600 The culture conditions were 28-30°C and 220 rpm. During the culture process, 2 mL of samples were taken every 24 h for analysis of growth OD 600 and lycopene production.

[0080] 2.3 Lycopene determination

[0081] Take 500μL of fermentation liquid and centrifuge at 12000rpm for 5min to remove the supernatant. Wash the precipitate twice with deionized water, and then add 1mL of 3M hydrochloric acid solution to resuspend the bacteria. Boil water bath for 4min, then ice bath for 3min, repeat once. After the ice bath, centrifuge at 12000rpm for 10min to remove the supernatant, wash the precipitate twice with deionized water, add 1mL of acetone and vortex mix thoroughly, then centrifuge at 12000rpm for 10min, take the supernatant and filter it with 0.22μm organic filter membrane, and then perform liquid phase quantitative analysis.

[0082] The cell concentration was determined by spectrophotometry using the absorbance at 600 nm.

[0083] The test results showed that the lycopene production of the engineered bacteria zw113 through YPD shake flask fermentation increased by 45.39% compared with the strain TX-L3, and the yield and yield reached 265.67 mg / L and 21.85 mg / g DCW, respectively.

[0084] Example 3: Construction of engineered bacteria zw137

[0085] Endogenous squalene synthase (ERG9p) competes with GGPPs for FPP precursors, limiting the production of lycopene. Therefore, it is necessary to rationally regulate ERG9 expression to balance the growth and production of engineered strains. Ubiquitination is a post-translational modification of proteins that can induce the degradation of target proteins, providing an alternative method for regulating gene expression. In order to balance cell growth and product synthesis, dynamic regulation of ERG20 is used to effectively synthesize monoterpenes in combination with sterol-responsive promoters and ubiquitination systems. However, sterol-responsive promoters have not yet been found in Pichia pastoris. Therefore, based on the sterol-responsive promoters identified in Saccharomyces cerevisiae, we screened homologous analogs in Pichia pastoris for subsequent experiments. In this example, we selected ERG1 (P ERG1 )、ERG2(P ERG2 )、ERG3(P ERG3 )、ERG7(P ERG7 ) and ERG8(P ERG8 ) promoter, and with the background promoter P ERG9 The strengths were compared.

[0086] 3.1 Construction of engineered bacteria

[0087] The engineered strain zw113 obtained in Example 1 was used as the starting strain, and the promoter of ERG9 (NCBI accession number: XM_002492490.1) encoding squalene synthase was replaced with P ERG8 -Ubi-KN113, and obtained the engineered bacteria zw137.

[0088] Among them, P ERG8 It is the promoter of the endogenous gene ERG8 (NCBI accession number: XM_002491823.1) encoding phosphomevalonate kinase in Pichia pastoris (1000 bp upstream of ERG8), Ubi is the endogenous ubiquitin protein gene (GenBank accession number: CAH2450568.1), and KN113 is the protein N-terminal degradation signal sequence.

[0089] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0090] Using zw113 as the chassis strain, the primers for amplifying the upstream homology arm were ERG9-UHA-F / ERG9-UHA-R, and the primers for the downstream homology arm were Ubi-F / ERG9-R. The upstream homology arm was amplified from the X33 yeast genome by PCR, and the downstream homology arm was amplified from the plasmid pGS624 by PCR. The promoter P ERG8The primers for ligating the sgRNA sequence to pGS327 are pERG8-F / pERG8-R; the primers for connecting the sgRNA sequence to pGS327 are gRNA-ERG9-F / gRNA-ERG9-R; and the primers for verification are ERG9-UHA-F / ERG9-R.

[0091] 3.2. YPD shake flask fermentation

[0092] Same as 2.2 of Example 2.

[0093] 3.3 Lycopene determination

[0094] Same as 2.3 of Example 2.

[0095] The test results showed that the lycopene production and yield of the engineered bacteria zw137 through YPD shake flask fermentation reached 452.71 mg / L and 47.26 mg / g DCW respectively.

[0096] Example 4. Construction of engineered bacteria zw205

[0097] The engineered zw137 obtained in Example 3 was used as the starting strain, and P GAP as promoter and T AOX1 The MVD1 gene (P GAP -MVD1-T AOX1 ) to obtain the engineered bacterium zw205; wherein the NCBI accession number of MVD1 is: XM_002490072.1).

[0098] 4.1 Construction of engineered bacteria

[0099] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0100] Using zw137 as the chassis strain, the primers for amplifying the upstream homology arm are II-6-UHA-F / II-6-UHA-R, and the primers for the downstream homology arm are II-6-DHA-F / II-6-DHA-R; the primers for connecting the sgRNA sequence to pGS327 are gRNA-II-6-F / gRNA-II-6-R; the expression cassette fragment P is amplified. GAP -MVD1-T AOX1 The primers were pGAP-F-II-6-UHA / AOX1TT-R-II-6-DHA, the template plasmid was pLT50; the verification primers were II-6-UHA-F / II-6-DHA-R.

[0101] 4.2. YPD shake flask fermentation

[0102] Same as 2.2 of Example 2.

[0103] 4.3 Lycopene determination

[0104] Same as 2.3 of Example 2.

[0105] The test results showed that the lycopene production and yield of the engineered bacteria zw205 through YPD shake flask fermentation reached 487.57 mg / L and 50.7 mg / g DCW respectively.

[0106] Example 5. Construction of engineered bacteria zw243

[0107] The engineered bacteria zw205 obtained in Example 4 was used as the starting strain, and P GAP as promoter and T PMP20 The ERG10 gene (P GAP -ERG10-T PMP20 ) to obtain the engineered bacterium zw243; wherein the NCBI accession number of ERG10 is: XM_002490381.1.

[0108] 5.1. Construction of engineered bacteria

[0109] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0110] Using zw205 as the chassis strain, the primers for amplifying the upstream homology arm were II-4-UHA-F / II-4-UHA-R, and the primers for the downstream homology arm were II-4-DHA-F / II-4-DHA-R; the primers for connecting the sgRNA sequence to pGS327 were gRNA-II-4-F / gRNA-II-4-R; the expression cassette fragment P was amplified GAP -ERG10-T PMP20 The primers were pGAP-F-II-4-UHA / PMP20TT-R-II-4-DHA, the template plasmid was pGS309; ​​the verification primers were II-4-UHA-F / II-4-DHA-R.

[0111] 5.2. YPD shake flask fermentation

[0112] Same as 2.2 of Example 2.

[0113] 5.3 Lycopene determination

[0114] Same as 2.3 of Example 2.

[0115] The test results showed that the lycopene production and yield of the engineered bacteria zw243 through YPD shake flask fermentation reached 600.77 mg / L and 57.43 mg / g DCW respectively.

[0116] Example 6: Construction of engineered bacteria zw267

[0117] The engineered bacterium zw243 obtained in Example 5 was used as the starting strain, and P GAP as promoter and T PMP20 The CrtE and ERG20 genes were linked by GGGGS as terminators (P GAP -CrtE-GGGGS-ERG20-T PMP20 ) to obtain the engineered bacterium zw267; wherein the NCBI accession number of the gene ERG20 is: XM_002490391.1.

[0118] 6.1. Construction of engineered bacteria

[0119] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0120] Using zw243 as the chassis strain, the primers for amplifying the upstream homology arm were III-4-UHA-F / III-4-UHA-R, and the primers for the downstream homology arm were III-4-DHA-F / III-4-DHA-R; the primers for connecting the sgRNA sequence to pGS327 were gRNA-III-4-F / gRNA-III-4-F; the expression cassette fragment P was amplified GAP -CrtE-GGGGS-ERG20-T PMP20 The primers were pGAP-F-III-4-UHA / PMP20TT-R-III-4-DHA, the template plasmid was pGS689; the verification primers were III-4-UHA-F / III-4-DHA-R.

[0121] 6.2. YPD shake flask fermentation

[0122] Same as 2.2 of Example 2.

[0123] 6.3 Lycopene determination

[0124] Same as 2.3 of Example 2.

[0125] The test results showed that the lycopene production and yield of the engineered bacteria zw267 through YPD shake flask fermentation reached 650.64 mg / L and 61.6 mg / g DCW respectively.

[0126] 6.4. MM shake flask fermentation

[0127] Pick a single colony of the engineered bacteria zw267 obtained in 6.1 above and grow on the plate, inoculate it into a 250 mL conical flask containing 15 mL MY medium and culture it for 24 to 36 h, then transfer it to a 250 mL conical flask containing 50 mL MM medium to control the initial OD 600 The culture conditions were 28-30°C and 220 rpm. Sterile methanol was added every 24 hours during the culture process to keep the methanol concentration in the culture medium at about 10 g / L. 2 mL of samples were taken every 48 hours for analysis of growth OD. 600 and lycopene production.

[0128] 6.5. Lycopene determination

[0129] Take 500 μL of the fermentation liquid obtained in 6.4 above and centrifuge at 12000 rpm for 5 min to remove the supernatant. After washing the precipitate twice with deionized water, add 1 mL of 3M hydrochloric acid solution to resuspend the bacteria. Boil in water for 4 min, then ice bath for 3 min, repeat once. After the ice bath, centrifuge at 12000 rpm for 10 min to remove the supernatant. After washing the precipitate twice with deionized water, add 1 mL of acetone and vortex thoroughly to mix. Centrifuge at 12000 rpm for 10 min, take the supernatant and filter it with a 0.22 μm organic filter membrane, and then perform liquid phase quantitative analysis.

[0130] The cell concentration was determined by spectrophotometry using the absorbance at 600 nm.

[0131] The test results showed that the lycopene production and yield of the engineered bacteria zw267 through MM shake flask fermentation reached 122.57 mg / L and 22.08 mg / g DCW respectively.

[0132] Example 7. Construction of engineered bacteria zw327

[0133] The engineered bacterium zw267 obtained in Example 6 was used as the starting strain, and P GAP as promoter and T PMP20 The PAS_Chr2-2_0003 gene (P GAP -PAS_Chr2-2_0003-T PMP20 ) to obtain the engineered bacterium zw327; wherein the NCBI accession number of the gene PAS_Chr2-2_0003 is: XM_002492168.1.

[0134] 7.1. Construction of engineered bacteria

[0135] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0136] Using zw267 as the chassis strain, the primers for amplifying the upstream homology arm are I-2-UHA-F / I-2-UHA-R, and the primers for the downstream homology arm are I-2-DHA-F / I-2-DHA-R; the primers for connecting the sgRNA sequence to pGS327 are gRNA-I-2-F / gRNA-I-2-R; the expression cassette fragment P is amplified. GAP -PAS_chr2-2_0003-T PMP20 The primers were pGAP-FI-2-UHA / PMP20TT-RI-2-DHA, the template plasmid was pGS669; the verification primers were I-2-UHA-F / I-2-DHA-R.

[0137] 7.2. YPD shake flask fermentation

[0138] Same as 2.2 of Example 2.

[0139] 7.3 Lycopene determination

[0140] Same as 2.3 of Example 2.

[0141] The test results showed that the lycopene production and yield of the engineered bacteria zw327 through YPD shake flask fermentation reached 745.4 mg / L and 70.88 mg / g DCW respectively.

[0142] Example 8. Construction of engineered bacteria zw303

[0143] The engineered bacteria zw267 obtained in Example 6 was used as the starting strain, and P AOX1 as promoter and T Gcw14 The DAS1 gene (P AOX1 -DAS1-T Gcw14 ), with P AOX1 as promoter and T TPI1 The RKI1 gene (P AOX1 -RKI1-T TPI1 ), and P AOX1 as promoter and T GCW14 The TAL2 gene (P AOX1 -TAL2-T GCW14 ) to obtain the engineered bacteria zw303; wherein the NCBI accession number of gene DAS1 is: XM_002493018.1, the NCBI accession number of RKI1 is: XM_002493573.1, and the NCBI accession number of TAL2 is: XM_002491803.1.

[0144] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0145] Using zw267 as the chassis strain, the primers for amplifying the upstream homology arm are II-5-UHA-F / II-5-UHA-R, and the primers for the downstream homology arm are II-5-DHA-F / II-5-DHA-R; the primers for connecting the sgRNA sequence to pGS327 are gRNA-II-5-F / gRNA-II-5-R; the expression cassette fragment P is amplified. AOX1 -DAS1-T Gcw14 , P AOX1 -RKI1-T TPI1 , P AOX1 -TAL2-T GCW14 The primers were pAOX1-F-II-5-UHA / Gcw14TT-R-pAOX1, pAOX1-F-Gcw14TT / TPI1TT-R-pAOX1, pAOX1-F-TPI1TT / Gcw14TT-R-II-5-DHA, and the template plasmids were pGS520, pGS490, and pGS489, respectively; segmented verification was performed, and the verification primers were II-5-UHA-F / DAS1-R2, DAS1-F2 / TPI1TT-R, and TPI1TT-F1 / II-5-DHA-R.

[0146] Example 9: Construction of engineered bacteria zw306

[0147] The engineered bacterium zw303 obtained in Example 8 was used as the starting strain, and P AOX1 as promoter and T DAS2 The AnXfpk gene (P AOX1 -AnXfpk-ePTS1-T DAS2 ), and P GAP as promoter and T TPI1 The gene BsuPta (P GAP -BsuPta-ePTS1-T TPI1 ) to obtain the engineered bacterium zw306; wherein the GenBank accession number of the gene AnXfpk is: XP_001399780.1, and the GenBank accession number of the gene BsuPta is: WP_003243393.1.

[0148] 9.1. Construction of engineered bacteria

[0149] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0150] Using zw303 as the chassis strain, the primers for amplifying the upstream homology arm are DL4-UHA-F2 / DL4-UHA-R2, and the primers for the downstream homology arm are DL4-DHA-F2 / DL4-DHA-R2; the primers for connecting the sgRNA sequence to pGS327 are gDL4-F / gDL4-R; the expression cassette fragment P is amplified. AOX1 -AnXfpk-ePTS1-T DAS2 , P GAP -BsuPta-ePTS1-T TPI1 The primers were pAOX1-F-DL4-UHA / DSA2TT-R-pGAP and pGAP-F-DAS2TT / TPI1TT-R-DL4-DHA, and the template plasmids were pGS459 and pGS455, respectively; segmented verification was performed, and the verification primers were DL4-DHA-F2 / DAS2TT-R and DAS2TT-F / DL4-DHA-R2.

[0151] 9.2. MM shake flask fermentation

[0152] Same as 6.4 of Example 6.

[0153] 9.3 Lycopene determination

[0154] Same as 6.5 of Example 6.

[0155] The test results showed that the lycopene production and yield of the engineered bacteria zw306 through MM shake flask fermentation reached 193.8 mg / L and 37.08 mg / g DCW respectively.

[0156] Example 10: Construction of engineered bacteria zw352

[0157] The engineered bacteria zw306 obtained in Example 9 was used as the starting strain, and P AOX1 as promoter and T PMP20 The terminator gene PAS_Chr2-2_0003 (P GAP -PAS_Chr2-2_0003-T PMP20 ) to obtain the engineered bacterium zw352; wherein the NCBI accession number of the gene PAS_Chr2-2_0003 is: XM_002492168.1.

[0158] 10.1、Construction of engineered bacteria

[0159] The specific operation steps refer to the engineering bacteria zw113, the difference is that the primers used are different, as follows:

[0160] Using zw306 as the chassis strain, the primers for amplifying the upstream homology arm are I-2-UHA-F / I-2-UHA-R, and the primers for the downstream homology arm are I-2-DHA-F / I-2-DHA-R; the primers for connecting the sgRNA sequence to pGS327 are gRNA-I-2-F / gRNA-I-2-R; the expression cassette fragment P is amplified. GAP -PAS_chr2-2_0003-T PMP20 The primers were pGAP-FI-2-UHA / PMP20TT-RI-2-DHA, the template plasmid was pGS669; the verification primers were I-2-UHA-F / I-2-DHA-R.

[0161] 10.2. MM shake flask fermentation

[0162] Same as 6.4 of Example 6.

[0163] 10.3 Lycopene determination

[0164] Same as 6.5 of Example 6.

[0165] The test results showed that the lycopene production and yield of the engineered bacteria zw352 through MM shake flask fermentation reached 227.27 mg / L and 40.95 mg / g DCW respectively.

[0166] Example 11: Evaluation of Lycopene Production Capacity of Engineering Bacteria zw327

[0167] In order to evaluate the lycopene production capacity of the engineered strain zw327, this example carried out fed-batch fermentation in a 5L tank fermenter. A single colony was first inoculated in a 250mL Erlenmeyer flask containing 50mL YPD medium and cultured at 30°C and 250rpm for about 20h. Then 4% (v / v) of the seed culture was transferred to a 500mL Erlenmeyer flask containing 100mL YPD medium and cultured under the same conditions and time. Finally, 8% (v / v) of the seed culture was inoculated into a 5L fermenter containing 0.05% (w / v) MgSO4 in YPD medium for batch fermentation. A solution containing 50% (w / v) glucose and 1% (w / v) yeast extract was used as the feeding strategy.

[0168] The fermentation process of this embodiment is divided into two stages: the cultured yeast seed liquid is inoculated into a 5L fully automatic mechanical stirring and ventilated fermentation tank (sterilized) at an inoculation rate of 8% (v / v), the initial culture medium volume is 2.5L, and it is sterilized at 121°C for 30 minutes. A 2M sodium hydroxide solution is used to control the pH at 6.0, the dissolved oxygen is maintained at 30%, the temperature is controlled at 30°C, the upper limit of the stirring speed is 400-800rpm, and the ventilation volume is set to 2vvm. When DO rises to more than 50%, fed-batch fermentation is started. The glucose concentration is maintained at 1 g / L by adjusting the feed rate. Samples are taken every 12 hours to measure the lycopene titer, glucose concentration and OD 600 .

[0169] The lycopene production of the recombinant strain zw327 was measured to be 8.4 g / L by the above-mentioned 5 L tank fed batch fermentation.

[0170] Example 12: Evaluation of Lycopene Production Capacity of Engineered Bacteria zw352

[0171] In order to evaluate the production capacity of the engineered strain zw352, this example carried out fed-batch fermentation in a 5L tank fermenter. A single colony was first inoculated in a 250mL Erlenmeyer flask containing 50mL YPD medium and cultured at 30°C and 250rpm for about 24 to 36h. Then 4% (v / v) of the seed culture was transferred to a 500mL Erlenmeyer flask containing 100mL YPD medium and cultured under the same conditions and time. Finally, 8% (v / v) of the seed culture was inoculated into the BSM medium of a 5L fermenter for batch fed fermentation. According to the reference scheme in the Pichia Fermentation Process Guide (Invitrogen), a 50% (w / v) glycerol solution containing 1.2% (v / v) PTM1 and a methanol solution containing 1.2% (v / v) PTM1 were used as the feeding strategy.

[0172] The fermentation process of this embodiment is divided into two stages: the cultured yeast seed liquid is inoculated into a 5L fully automatic mechanical stirring and ventilated fermentation tank (sterilized) at an inoculation rate of 8% (v / v), and glycerol is added to start bacterial growth (the volume of the initial culture medium is 2.5L, sterilized at 121°C for 30min). (1) Bacterial growth stage: Use 25% concentrated ammonia water to control its pH at 5.5, maintain dissolved oxygen at 30-60%, control the temperature at 30°C, stir at 400-800rpm, and set the ventilation volume to 3vvm. Initial cell density OD 600 When the DO reaches about 160, stop adding glycerol. When DO rises to above 80% again, start methanol feeding to induce fermentation.

[0173] Methanol addition stage: the temperature was controlled at 30°C, the pH was controlled at 6.0 using 25% concentrated ammonia water, the rotation speed was controlled at 800rpm, the ventilation volume was controlled at 3vvm, and methanol containing 12mL / L PTM1 was added to the bioreactor at a rate of 15g / h to induce fermentation.

[0174] The lycopene production of the engineered strain zw352 was measured to be 10.2 g / L by the above-mentioned 5 L tank fed batch fermentation.

[0175] The preferred embodiments of the present invention are described in detail above. In the process of completing the invention, many metabolic pathway modification strategies were tried, but many of them failed to achieve the expected results. This specification only describes in detail the engineered bacteria in which the lycopene production is significantly improved. This is hereby explained.

Claims

1. A genetically engineered Pichia pastoris zw113 with high lycopene production, It is characterized in that The engineering bacterium zw113 is based on the Pichia pastoris strain TX-L3 as the starting strain, and the III-10 site is integrated with P GAP and T DAS2 The CrtI gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused to the C-terminus. GAP -CrtI-ePTS1-T DAS2 , respectively, with P GAP and T FBA1 The CrtYB gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused at the C-terminus. GAP -CrtYB W61R -ePTS1-T FBA1 , and P GAP and T CAT1TT The CrtE gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused at the C terminus. GAP -CrtE-ePTS1-T CAT1TT And get, among which: The GenBank accession number of gene CrtI is: AY177424.1, the GenBank accession number of gene CrtYB is: AY177204.1, the GenBank accession number of gene CrtE is: DQ016502.1, and the above genes have been codon-optimized according to the preference of Pichia pastoris.

2. A genetically engineered Pichia pastoris zw137 with high lycopene production, It is characterized in that The engineered bacterium zw137 is based on the engineered bacterium zw113 described in claim 1 as the starting strain, and the promoter of ERG9 encoding squalene synthase is replaced by P ERG8 -Ubi-KN113, where: P ERG8 It is the promoter of the endogenous gene ERG8 encoding phosphomevalonate kinase in Pichia pastoris, and the NCBI accession number of the gene ERG8 is XM_002491823.1; Ubi is an endogenous ubiquitin protein gene, and its GenBank accession number is CAH2450568.1; KN113 is a protein N-terminal degradation signal sequence.

3. A genetically engineered Pichia pastoris zw205 with high lycopene production, It is characterized in that The engineered bacterium zw205 is based on the engineered zw137 described in claim 2 as the starting strain, and the II-6 sites are integrated with P GAP and T AOX1 MVD1 gene P GAP -MVD1-T AOX1 The NCBI accession number of MVD1 is: XM_002490072.

1.

4. A genetically engineered Pichia pastoris zw243 with high lycopene production, It is characterized in that The engineered bacterium zw243 is based on the engineered bacterium zw205 described in claim 3 as the starting strain, and the II-4 sites are integrated with P GAP and T PMP20 ERG10 gene P GAP -ERG10-T PMP20 The NCBI accession number of ERG10 is: XM_002490381.

1.

5. A genetically engineered Pichia pastoris zw267 with high lycopene production, It is characterized in that The engineered bacterium zw267 is based on the engineered bacterium zw243 described in claim 4 as the starting strain, and the III-4 sites are integrated with P GAP and T PMP20 The CrtE and ERG20 genes are linked by GGGGS. GAP -CrtE-GGGGS-ERG20-T PMP20 It was obtained that the NCBI accession number of gene ERG20 is: XM_002490391.

1.

6. A genetically engineered Pichia pastoris zw327 with high lycopene production, It is characterized in that The engineered bacterium zw327 is based on the engineered bacterium zw267 described in claim 5 as the starting strain, and the P GAP and T PMP20 PAS_Chr2-2_0003 gene P GAP -PAS_Chr2-2_0003-T PMP20 The NCBI accession number of gene PAS_Chr2-2_0003 is: XM_002492168.

1.

7. A genetically engineered Pichia pastoris zw303 with high lycopene production, It is characterized in that The engineered bacterium zw303 is based on the engineered bacterium zw267 described in claim 5 as the starting strain, and P AOX1 and T Gcw14 The DAS1 gene P AOX1 -DAS1-T Gcw14 , respectively, P AOX1 and T TPI1 The promoter and terminator of the RKI1 gene P AOX1 -RKI1-T TPI1 , and P AOX1 and T GCW14 TAL2 gene P AOX1 -TAL2-T GCW14 And get, among which: The NCBI accession number of gene DAS1 is: XM_002493018.1, the NCBI accession number of RKI1 is: XM_002493573.1, and the NCBI accession number of TAL2 is: XM_002491803.

1.

8. A genetically engineered Pichia pastoris zw306 with high lycopene production, It is characterized in that The engineered bacterium zw306 is based on the engineered bacterium zw303 described in claim 7 as the starting strain, and the DNA ligase IV site is integrated with P AOX1 and T DAS2 The AnXfpk gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused at the C-terminus. AOX1 -AnXfpk-ePTS1-T DAS2 , and P GAP and T TPI1 The BsuPta gene P is a promoter and terminator, and the peroxisome targeting signal peptide ePTS1 is fused to the C-terminus. GAP -BsuPta-ePTS1-T TPI1 And get, among which: The GenBank accession number of gene AnXfpk is: XP_001399780.1, and the GenBank accession number of gene BsuPta is: WP_003243393.

1.

9. A genetically engineered Pichia pastoris zw352 with high lycopene production, It is characterized in that The engineered bacterium zw352 is based on the engineered bacterium zw303 described in claim 7 as the starting strain, and the P AOX1 and T PMP20 PAS_Chr2-2_0003 gene P GAP -PAS_Chr2-2_0003-T PMP20 The NCBI accession number of gene PAS_Chr2-2_0003 is: XM_002492168.1.